Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma
Objectives: Bone disease is a key presenting feature of myeloma. This post hoc analysis of the phase III VISTA trial of bortezomib plus melphalan-prednisone (VMP) vs. MP in previously untreated myeloma patients assessed clinical bone disease events and changes in alkaline phosphatase (ALP), a marker...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2011
|
| In: |
European journal of haematology
Year: 2011, Jahrgang: 86, Heft: 5, Pages: 372-384 |
| ISSN: | 1600-0609 |
| DOI: | 10.1111/j.1600-0609.2011.01599.x |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1111/j.1600-0609.2011.01599.x Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-0609.2011.01599.x 
|
| Verfasserangaben: | Michel Delforge, Evangelos Terpos, Paul G. Richardson, Ofer Shpilberg, Nuriet K. Khuageva, Rudolf Schlag, Meletios A. Dimopoulos, Martin Kropff, Ivan Spicka, Maria T. Petrucci, Olga S. Samoilova, Maria-Victoria Mateos, Hila Magen-Nativ, Hartmut Goldschmidt, Dixie-Lee Esseltine, Deborah S. Ricci, Kevin Liu, William Deraedt, Andrew Cakana, Helgi van de Velde, Jesús F. San Miguel |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1800861621 | ||
| 003 | DE-627 | ||
| 005 | 20230428020639.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220504s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/j.1600-0609.2011.01599.x |2 doi | |
| 035 | |a (DE-627)1800861621 | ||
| 035 | |a (DE-599)KXP1800861621 | ||
| 035 | |a (OCoLC)1341459585 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Delforge, Michel |e VerfasserIn |0 (DE-588)1256780138 |0 (DE-627)1800861524 |4 aut | |
| 245 | 1 | 0 | |a Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma |c Michel Delforge, Evangelos Terpos, Paul G. Richardson, Ofer Shpilberg, Nuriet K. Khuageva, Rudolf Schlag, Meletios A. Dimopoulos, Martin Kropff, Ivan Spicka, Maria T. Petrucci, Olga S. Samoilova, Maria-Victoria Mateos, Hila Magen-Nativ, Hartmut Goldschmidt, Dixie-Lee Esseltine, Deborah S. Ricci, Kevin Liu, William Deraedt, Andrew Cakana, Helgi van de Velde, Jesús F. San Miguel |
| 246 | 3 | 0 | |a versus three |
| 264 | 1 | |c 2011 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 04.05.2022 | ||
| 520 | |a Objectives: Bone disease is a key presenting feature of myeloma. This post hoc analysis of the phase III VISTA trial of bortezomib plus melphalan-prednisone (VMP) vs. MP in previously untreated myeloma patients assessed clinical bone disease events and changes in alkaline phosphatase (ALP), a marker for osteoblast activation, and serum Dickkopf-1 (DKK-1), an inhibitor of osteoblast differentiation, during treatment. Methods: Patients received nine 6-wk cycles of VMP (bortezomib 1.3 mg/m2, days 1, 4, 8, 11, 22, 25, 29, 32, cycles 1-4, days 1, 8, 22, 29, cycles 5-9, plus melphalan 9 mg/m2 and prednisone 60 mg/m2, days 1-4, cycles 1-9; N = 344) or MP alone (N = 338). Results: Rates of bisphosphonates use during treatment (73% vs. 82%), progression because of worsening bone disease (3% vs. 11%), and requirement for subsequent radiotherapy (3% vs. 8%) were lower with VMP vs. MP. Median maximum ALP increase was significantly higher with VMP vs. MP overall (49.7% vs. 30.3%, P = 0.029), and higher by response group (complete response [CR]: 68.7% vs. 43.9%; partial response [PR]: 41.5% vs. 31.2%). Greater maximum ALP increase was strongly associated with achievement of CR (P ≤ 0.0001) and CR/PR (P ≤ 0.01). Median DKK-1 decreased with VMP by 694.4 pg/mL and increased with MP by 1273.3 pg/mL from baseline to day 4 (P = 0.0069). Available radiologic data revealed evidence of bone healing in 6/11 VMP-treated patients, who achieved best responses of three CR, one PR, and two stable disease. Conclusions: These results suggest a positive effect of bortezomib on bone metabolism and potentially bone healing in myeloma. | ||
| 650 | 4 | |a bone | |
| 650 | 4 | |a bortezomib | |
| 650 | 4 | |a melphalan-prednisone | |
| 650 | 4 | |a myeloma | |
| 650 | 4 | |a VISTA | |
| 700 | 1 | |a Terpos, Evangelos |e VerfasserIn |4 aut | |
| 700 | 1 | |a Richardson, Paul G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shpilberg, Ofer |e VerfasserIn |4 aut | |
| 700 | 1 | |a Khuageva, Nuriet K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schlag, Rudolf |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dimopoulos, Meletios A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kropff, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Spicka, Ivan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Petrucci, Maria T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Samoilova, Olga S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mateos, Maria-Victoria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Magen-Nativ, Hila |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Esseltine, Dixie-Lee |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ricci, Deborah S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Liu, Kevin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Deraedt, William |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cakana, Andrew |e VerfasserIn |4 aut | |
| 700 | 1 | |a van de Velde, Helgi |e VerfasserIn |4 aut | |
| 700 | 1 | |a San Miguel, Jesús F. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of haematology |d Oxford : Wiley-Blackwell, 1987 |g 86(2011), 5, Seite 372-384 |h Online-Ressource |w (DE-627)320983463 |w (DE-600)2027114-1 |w (DE-576)093888864 |x 1600-0609 |7 nnas |a Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma |
| 773 | 1 | 8 | |g volume:86 |g year:2011 |g number:5 |g pages:372-384 |g extent:13 |a Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma |
| 856 | 4 | 0 | |u https://doi.org/10.1111/j.1600-0609.2011.01599.x |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-0609.2011.01599.x |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220504 | ||
| 993 | |a Article | ||
| 994 | |a 2011 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |d 50000 |e 910000PG102258023X |e 910100PG102258023X |e 50000PG102258023X |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 14 | ||
| 999 | |a KXP-PPN1800861621 |e 4129121332 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.1111/j.1600-0609.2011.01599.x"],"eki":["1800861621"]},"name":{"displayForm":["Michel Delforge, Evangelos Terpos, Paul G. Richardson, Ofer Shpilberg, Nuriet K. Khuageva, Rudolf Schlag, Meletios A. Dimopoulos, Martin Kropff, Ivan Spicka, Maria T. Petrucci, Olga S. Samoilova, Maria-Victoria Mateos, Hila Magen-Nativ, Hartmut Goldschmidt, Dixie-Lee Esseltine, Deborah S. Ricci, Kevin Liu, William Deraedt, Andrew Cakana, Helgi van de Velde, Jesús F. San Miguel"]},"physDesc":[{"extent":"13 S."}],"relHost":[{"part":{"year":"2011","pages":"372-384","text":"86(2011), 5, Seite 372-384","issue":"5","volume":"86","extent":"13"},"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myelomaEuropean journal of haematology","title":[{"title":"European journal of haematology","title_sort":"European journal of haematology"}],"pubHistory":["38.1987 -"],"note":["Gesehen am 08.05.09"],"origin":[{"publisherPlace":"Oxford ; Copenhagen ; Oxford [u.a.]","dateIssuedDisp":"1987-","publisher":"Wiley-Blackwell ; Munksgaard ; Blackwell","dateIssuedKey":"1987"}],"id":{"doi":["10.1111/(ISSN)1600-0609"],"zdb":["2027114-1"],"issn":["1600-0609"],"eki":["320983463"]},"recId":"320983463","physDesc":[{"extent":"Online-Ressource"}]}],"recId":"1800861621","type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 04.05.2022"],"origin":[{"dateIssuedDisp":"2011","dateIssuedKey":"2011"}],"title":[{"title":"Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma","title_sort":"Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma"}],"language":["eng"],"person":[{"role":"aut","given":"Michel","display":"Delforge, Michel","family":"Delforge"},{"display":"Terpos, Evangelos","family":"Terpos","role":"aut","given":"Evangelos"},{"role":"aut","given":"Paul G.","family":"Richardson","display":"Richardson, Paul G."},{"given":"Ofer","role":"aut","family":"Shpilberg","display":"Shpilberg, Ofer"},{"display":"Khuageva, Nuriet K.","family":"Khuageva","given":"Nuriet K.","role":"aut"},{"family":"Schlag","display":"Schlag, Rudolf","given":"Rudolf","role":"aut"},{"family":"Dimopoulos","display":"Dimopoulos, Meletios A.","role":"aut","given":"Meletios A."},{"display":"Kropff, Martin","family":"Kropff","given":"Martin","role":"aut"},{"given":"Ivan","role":"aut","display":"Spicka, Ivan","family":"Spicka"},{"role":"aut","given":"Maria T.","display":"Petrucci, Maria T.","family":"Petrucci"},{"family":"Samoilova","display":"Samoilova, Olga S.","given":"Olga S.","role":"aut"},{"display":"Mateos, Maria-Victoria","family":"Mateos","role":"aut","given":"Maria-Victoria"},{"family":"Magen-Nativ","display":"Magen-Nativ, Hila","given":"Hila","role":"aut"},{"display":"Goldschmidt, Hartmut","family":"Goldschmidt","given":"Hartmut","role":"aut"},{"display":"Esseltine, Dixie-Lee","family":"Esseltine","given":"Dixie-Lee","role":"aut"},{"family":"Ricci","display":"Ricci, Deborah S.","role":"aut","given":"Deborah S."},{"given":"Kevin","role":"aut","family":"Liu","display":"Liu, Kevin"},{"given":"William","role":"aut","display":"Deraedt, William","family":"Deraedt"},{"family":"Cakana","display":"Cakana, Andrew","given":"Andrew","role":"aut"},{"role":"aut","given":"Helgi","display":"van de Velde, Helgi","family":"van de Velde"},{"display":"San Miguel, Jesús F.","family":"San Miguel","role":"aut","given":"Jesús F."}]} | ||
| SRT | |a DELFORGEMIFEWERBONED2011 | ||